Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jul 2025 According to Idorsia Pharmaceuticals media release, anounced that the results of the Chinese Phase III clinical trial of QUVIVIQ (Daridorexant Tablets), were recently published in SLEEP, the official journal of the Sleep Research Society
30 Oct 2024 Status changed from active, no longer recruiting to completed.
25 Jul 2024 According to Idorsia Pharmaceuticals media release, positive phase 3 by Simcere in Greater China NDA submitted.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com